Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 891-900 of 2809 for

Edit search filters
  1. A Study of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment for Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors

  3. A Study to See if New Device Technology Can Tell the Difference Between Non-cancer and Cancerous Melanoma

    Scottsdale/Phoenix, AZ

  4. Combination Chemotherapy and Trastuzumab in Treating Women With Metastatic Breast Cancer

  5. Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

    Rochester, MN

  7. Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma

    Rochester, MN

  8. Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

    Rochester, MN

  9. PF-04449913 Single-Agent In Patients with Myelofibrosis Previously Treated with a Janus Kinase Inhibitor

    Scottsdale/Phoenix, AZ, Jacksonville, FL

  10. A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients

    Rochester, MN

.

Mayo Clinic Footer